VKTX
Viking Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.41
+5.05%Oct 29, 2026, 17:56 UTC
Viking Therapeutics, Inc. reported a wider third-quarter loss as rising clinical expenses weighed on results.
Source:Oct 28, 2026, 20:05 UTC
Viking Therapeutics, Inc. reported financial results for the third quarter and nine months ended September 30, 2026, and reported a quarter-end cash position of $960 million.
Source:Oct 28, 2026, 20:05 UTC
Viking Therapeutics, Inc. announced positive top-line results from its VK2735 maintenance dosing study and initiated Part 2 of the study.
Source:Oct 28, 2026, 20:05 UTC
Viking Therapeutics, Inc. said its VANQUISH Phase 3 trials of subcutaneous VK2735 in obesity continued to advance, its SUNRISE Phase 3 trials of oral VK2735 had been initiated, and a Phase 1 SAD study of VK3019 was nearing completion.
Source:Oct 22, 2026, 22:51 UTC
Viking Therapeutics shares fell 2.35% to $25.76 from the preceding trading day’s close.
Source:Oct 21, 2026, 20:05 UTC
Viking Therapeutics, Inc. announced that it will release its third-quarter 2026 financial results after the market close on October 28, 2026.
Source:Oct 16, 2026, 22:46 UTC
Viking Therapeutics shares closed at $25.11, down 8.26% from the previous close.
Source:Oct 9, 2026, 22:45 UTC
Viking Therapeutics shares rose 2.88% from the previous close to settle at $28.53.
Source:Oct 8, 2026, 22:50 UTC
Viking Therapeutics shares fell 2.84% to $27.73 from the preceding trading day.
Source:Oct 1, 2026, 22:46 UTC
Viking Therapeutics, Inc. (VKTX) shares fell 6.41% to close at $30.51 on the most recent trading day.
Source:Sep 28, 2026, 15:12 UTC
Kuehn Law, PLLC is investigating whether certain officers and directors of Viking Therapeutics, Inc. breached their fiduciary duties to shareholders.
Source:Sep 24, 2026, 15:58 UTC
Viking Therapeutics shares fell 15.20%, or $6.33, to $35.32 on Thursday on the Nasdaq after the equity and convertible notes offering was priced.
Source:Sep 24, 2026, 14:48 UTC
Viking Therapeutics announced a $500 million capital raise consisting of 7.86 million common shares at $35 per share and $225 million of 2.00% convertible notes due 2032.
Sep 23, 2026, 20:54 UTC
Viking Therapeutics shares gained over 40% in two days after the company reported positive results for its weight-loss drug candidate.
Source:Sep 23, 2026, 20:32 UTC
Viking Therapeutics announced its intention to offer $200.0 million of common stock and $200.0 million aggregate principal amount of convertible senior notes due 2032 in separate public offerings.
Source:Sep 22, 2026, 15:05 UTC
Viking Therapeutics reported trial data showing its obesity drug VK2735 maintained most patients' initial weight loss with less frequent dosing, sending its shares up over 27%.
Sep 22, 2026, 14:23 UTC
Viking Therapeutics said its injectable obesity candidate remained efficacious in a Phase 2 trial after transitioning from weekly to every-other-week or monthly dosing.
Source:Sep 22, 2026, 12:22 UTC
Viking Therapeutics announced positive results from its VK2735-102 maintenance therapy trial for the dual GLP-1/GIP agonist VK2735, sending its shares up 20.6% in after-hours trading.
Sep 22, 2026, 11:05 UTC
Viking Therapeutics announced positive topline results from a maintenance study of its GLP-1/GIP agonist VK2735, showing 22% placebo-adjusted weight loss at week 33 with weekly 17.5 mg dosing and maintained weight loss with monthly and every-other-week regimens.
Source:Jul 29, 2026, 20:05 UTC
Viking Therapeutics announced its financial results for the second quarter and six months ended June 30, 2026.
Jun 25, 2026, 15:01 UTC
Viking Therapeutics initiated a Phase I clinical study for its new obesity drug VK3019.
Source:Jun 11, 2026, 11:05 UTC
Viking Therapeutics appointed Hubert C. Chen, M.D. as a new executive.
Source: